ArticleCNS neuroscience & therapeutics2026
Tacrolimus as Single-Agent Immunotherapy for Adult-Onset Myasthenia Gravis: Remission, Relapse, and Safety.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
aimsTo identify factors influencing remission and relapse, and to evaluate the safety of tacrolimus monotherapy (TAMO) in adult-onset mild-to-moderate myasthenia gravis (MG).
methodsThis retrospective analysis was conducted on MG patients receiving TAMO. Remission was defined as achieving minimal symptom expression (MSE), and multivariable Cox regression analysis identified predictors of remission and relapse. Cancer risk was assessed by standardized incidence ratio (SIR), based on the age-specific cancer incidence rates in China in 2022.
resultsAmong 153 patients, 77.8% achieved MSE, with a median time of 6.0 months. Age at onset (hazard ratio [HR] = 0.982, 95% confidence interval [CI] = 0.968-0.995, p = 0.009) and new-onset MG (HR = 2.065, 95% CI = 1.266-3.368, p = 0.004) were independent predictors of time to achieving MSE. The optimal cut-off value for age at onset was 70 years. Relapse occurred in 31% of patients. Tacrolimus concentration at MSE (HR = 0.815, 95% CI = 0.695-0.956, p = 0.012) and dose reduction speed (HR = 1.717, 95% CI = 1.280-2.305, p < 0.001) were independent predictors of relapse. The cut-off values were 5.30 ng/mL and 1.08 mg/year, respectively. Adverse drug reactions (ADRs) occurred in 45.0% of the 200 patients receiving TAMO, with hyperglycemia being the most common (17.5%). Eight patients developed cancer, and the SIR was 2.86 (95% CI = 1.23-5.63, p = 0.005) compared with the general Chinese population.
conclusionTAMO was associated with higher rates of MSE in adult-onset mild-to-moderate MG patients with new-onset disease or with an onset age ≤ 70 years. To avoid MG relapse, tacrolimus concentration > 5.30 ng/mL at MSE and dose reduction speed ≤ 1.08 mg/year can be considered. Cancer surveillance may be considered for elderly patients undergoing long-term tacrolimus therapy. Limitations include the retrospective, uncontrolled design, moderate sample sizes, and limited follow-up duration; thus, long-term safety, particularly cancer risk, requires further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.